Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) ("Kiniksa," "we," and "our") announced the pricing of its public offering of 2,400,000 of its Class A common shares at a public offering price of $18.25 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering, together with the proceeds from the sale of 1,600,000 Class A1 common shares at the public offering price in a concurrent private placement, before fees and estimated expenses, are expected to be $73,000,000. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 360,000 additional Class A common shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on May 18, 2020, subject to customary closing conditions. All of the Class A common shares are being offered by Kiniksa.
Kiniksa intends to use the net proceeds from the public offering and the concurrent private placement to advance the clinical development of its product candidates, to fund other research and development activities and for working capital and general corporate purposes.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and BofA Securities are acting as joint book-running managers for the public offering. Wedbush Securities Inc. and JMP Securities LLC are acting as co-managers for the public offering.